Latest news

• Dermira craters as acne drug fails late-stage test

  s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is

• Roche out-licenses lebrikizumab rights to Dermira

  Meanwhile, Pfizer is starting to make headway with its new topical treatment Eucrisa (crisaborole), which pulled in $17m in the first half of the year after its approval last December.

• Regeneron bags US approval for eczema drug Dupixent

  Dupixent's approval comes just a few weeks after Pfizer won a green light from the regulator for Eucrisa (crisaborole) for patients with milder forms of atopic dermatitis - which the company

• Novartis adds oral eczema drug with Ziarco acquisition

  The deal comes hard on the heels of Pfizer gaining FDA approval of its Eucrisa (crisaborole) topical treatment for eczema - also known as atopic dermatitis - which is predicted to become a

• FDA green light for Pfizer's eczema drug

  FDA green light for Pfizer's eczema drug. Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube. ... The pharma leviathan has priced Eucrisa at $580 for a 60g tube, before any discounts or rebates, and expects to launch it